What is the effect of Fenofibrate on apoprotein C-III?

Fenofibrate is a medication primarily used to lower lipid levels, particularly in cases of hyperlipidemia. It acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) activator, which leads to various metabolic changes in the body, particularly affecting lipid metabolism.

One significant effect of Fenofibrate is its ability to lower the levels of apoprotein C-III (ApoC-III), a protein that is involved in the metabolism of triglycerides. ApoC-III plays a role in inhibiting lipoprotein lipase, which is crucial for breaking down triglycerides in the bloodstream. By lowering the levels of ApoC-III, Fenofibrate enhances the activity of lipoprotein lipase, thereby promoting the clearance of triglyceride-rich lipoproteins from the circulation.

The inhibition of ApoC-III activity, achieved through decreased levels of this protein, leads to improved lipid profiles in patients treated with Fenofibrate. This action is particularly beneficial as elevated levels of ApoC-III are associated with an increased risk of cardiovascular diseases due to their role in triglyceride metabolism and atherogenesis.

In summary, the correct answer is that Fenofibrate inhibits the activity of apoprotein C